Impact of Antihypertensive Medication Changes after Renal Denervation among Different Patient Groups: SPYRAL HTN-ON MED

Raymond R. Townsend, Keith C. Ferdinand, David E. Kandzari, Kazuomi Kario, Felix Mahfoud, Michael A. Weber, Roland E. Schmieder, Stuart Pocock, Konstantinos Tsioufis, Shukri David, Susan Steigerwalt, Antony Walton, Ingrid Hopper, Barry Bertolet, Faisal Sharif, Karl Fengler, Martin Fahy, Douglas A. Hettrick, Sandeep Brar, Michael Böhm

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)

Abstract

BACKGROUND: The SPYRAL HTN-ON MED (Global Clinical Study of Renal Denervation With the Symplicity Spyral Multi-electrode Renal Denervation System in Patients With Uncontrolled Hypertension in the Absence of Antihypertensive Medications)trial showed significant office and nighttime systolic blood pressure (BP) reductions in patients with hypertension following renal denervation (RDN) compared with sham-control patients, despite similar 24-hour BP reductions. We compared antihypertensive medication and BP changes among prespecified subpopulations. METHODS: The multicenter, randomized, sham-controlled, blinded SPYRAL HTN-ON MED trial (n=337) evaluated BP changes after RDN compared with a sham procedure in patients with hypertension prescribed 1 to 3 antihypertensive drugs. Most patients (n=187; 54%) were enrolled outside the United States, while 156 (46%) US patients were enrolled, including 60 (18%) Black Americans. RESULTS: Changes in detected antihypertensive drugs were similar between RDN and sham group patients in the outside US cohort, while drug increases were significantly more common in the US sham group compared with the RDN group. Patients from outside the United States showed significant reductions in office and 24-hour mean systolic BP at 6 months compared with the sham group, whereas BP changes were similar between RDN and sham in the US cohort. Within the US patient cohort, Black Americans in the sham control group had significant increases in medication burden from baseline through 6 months (P=0.003) but not in the RDN group (P=0.44). CONCLUSIONS: Patients enrolled outside the United States had minimal antihypertensive medication changes between treatment groups and had significant office and 24-hour BP reductions compared with the sham group. Increased antihypertensive drug burden in the US sham cohort, especially among Black Americans, may have diluted the treatment effect in the combined trial population. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02439775.

Original languageEnglish
Pages (from-to)1095-1105
Number of pages11
JournalHypertension
Volume81
Issue number5
DOIs
Publication statusPublished - 1 May 2024
Externally publishedYes

Keywords

  • antihypertensive agents
  • Black or African American
  • blood pressure
  • hypertension
  • renal denervation

Cite this